<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>metabolic vulnerability targeting &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/metabolic-vulnerability-targeting/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 09:52:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>metabolic vulnerability targeting &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Aramchol Enhances Regorafenib Efficacy in Treating Gastrointestinal Tumors</title>
		<link>https://bioengineer.org/aramchol-enhances-regorafenib-efficacy-in-treating-gastrointestinal-tumors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 19 Aug 2025 19:02:09 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[gastrointestinal cancer combination therapy]]></category>
		<category><![CDATA[genetic variant-driven oncology]]></category>
		<category><![CDATA[metabolic vulnerability targeting]]></category>
		<category><![CDATA[regorafenib efficacy enhancement]]></category>
		<category><![CDATA[SCD1 inhibitor drug synergy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/aramchol-enhances-regorafenib-efficacy-in-treating-gastrointestinal-tumors/</guid>

					<description><![CDATA[A groundbreaking study published in the latest volume of Oncotarget reveals a promising therapeutic synergy between aramchol, an emerging SCD1 inhibitor, and regorafenib, a multi-kinase inhibitor already established in cancer treatment. This novel drug combination demonstrates enhanced efficacy against gastrointestinal (GI) tumors, specifically targeting liver and colorectal cancers, both in vitro and in vivo. The [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">256401</post-id>	</item>
	</channel>
</rss>
